Published on
Apr 6, 2025
Confirming the Benefit of SGLT2 Inhibitors in People With ATTR Amyloidosis, with Justin Riley Lam, MD
Although SGLT2 inhibitors have become standard in the management of heart failure with preserved and reduced ejection fraction, their use in patients with ATTR amyloidosis with cardiac disease remains largely unstudied. Most major trials have excluded this …
Source:
Consultant Live
-
Label Pending
